Literature DB >> 31232703

Bypassing the bottleneck: intentional hepatitis C transmission with organ transplant.

Christine M Durand, Michael A Chattergoon.   

Abstract

Solid organ transplantation from hepatitis C virus-positive (HCV-positive) deceased donors into HCV-negative recipients is a recent approach aimed to expand the donor organ pool in the setting of severe shortage. Good short-term outcomes have been reported with this approach in combination with direct-acting antivirals. In this issue of the JCI, Zahid and colleagues have characterized early viral kinetics and the genetic landscape of donor-to-recipient HCV transmission using single-genome sequencing. In seven HCV-negative recipients of four HCV-positive donor organs, productive infection with a highly diverse viral population was seen by day three after transplantation. The degree of genetic diversity seen in recipients of HCV-positive organs was unlike the narrow genetic bottleneck typically observed with acute HCV acquisition from intravenous drug use or sexual activity. All recipients achieved HCV cure with treatment. The consequences of acute infection with a genetically diverse HCV population are unknown; however, early clinical experience with this transplantation strategy is promising.

Entities:  

Year:  2019        PMID: 31232703      PMCID: PMC6668816          DOI: 10.1172/JCI129982

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  19 in total

1.  Transplanting Hepatitis C-Positive Kidneys.

Authors:  Peter P Reese; Peter L Abt; Emily A Blumberg; David S Goldberg
Journal:  N Engl J Med       Date:  2015-07-23       Impact factor: 91.245

2.  High multiplicity infection following transplantation of hepatitis C virus-positive organs.

Authors:  Muhammad N Zahid; Shuyi Wang; Gerald H Learn; Peter L Abt; Emily A Blumberg; Peter P Reese; David S Goldberg; George M Shaw; Katharine J Bar
Journal:  J Clin Invest       Date:  2019-05-21       Impact factor: 14.808

3.  Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing.

Authors:  Arunasingam Abayasingam; Preston Leung; Auda Eltahla; Rowena A Bull; Fabio Luciani; Jason Grebely; Gregory J Dore; Tanya Applegate; Kimberly Page; Julie Bruneau; Andrea L Cox; Arthur Y Kim; Janke Schinkel; Naglaa H Shoukry; Georg M Lauer; Lisa Maher; Margaret Hellard; Maria Prins; Andrew Lloyd; Chaturaka Rodrigo
Journal:  Infect Genet Evol       Date:  2019-03-08       Impact factor: 3.342

4.  Early outcomes using hepatitis C-positive donors for cardiac transplantation in the era of effective direct-acting anti-viral therapies.

Authors:  Kelly H Schlendorf; Sandip Zalawadiya; Ashish S Shah; Mark Wigger; Chan Y Chung; Sarah Smith; Matthew Danter; Chun W Choi; Mary E Keebler; D Marshall Brinkley; Suzanne Brown Sacks; Henry Ooi; Roman Perri; Joseph A Awad; Samuel Lewis; Rachel Hayes; Heather O'Dell; Callie Darragh; Alicia Carver; Cori Edmonds; Shelley Ruzevich-Scholl; JoAnn Lindenfeld
Journal:  J Heart Lung Transplant       Date:  2018-01-31       Impact factor: 10.247

5.  Changes in Utilization and Discard of HCV Antibody-Positive Deceased Donor Kidneys in the Era of Direct-Acting Antiviral Therapy.

Authors:  Mary G Bowring; Lauren M Kucirka; Allan B Massie; Tanveen Ishaque; Sunjae Bae; Ashton A Shaffer; Jacqueline Garonzik Wang; Mark Sulkowski; Niraj Desai; Dorry L Segev; Christine M Durand
Journal:  Transplantation       Date:  2018-12       Impact factor: 4.939

6.  Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late.

Authors:  Adriano M Pellicelli; Marzia Montalbano; Raffaella Lionetti; Christine Durand; Peter Ferenci; Gianpiero D'Offizi; Viola Knop; Andrea Telese; Ilaria Lenci; Arnaldo Andreoli; Stefan Zeuzem; Mario Angelico
Journal:  Dig Liver Dis       Date:  2014-07-03       Impact factor: 4.088

7.  Changes in Utilization and Discard of Hepatitis C-Infected Donor Livers in the Recent Era.

Authors:  M G Bowring; L M Kucirka; A B Massie; X Luo; A Cameron; M Sulkowski; K Rakestraw; A Gurakar; I Kuo; D L Segev; C M Durand
Journal:  Am J Transplant       Date:  2016-08-24       Impact factor: 8.086

8.  The Drug Overdose Epidemic and Deceased-Donor Transplantation in the United States: A National Registry Study.

Authors:  Christine M Durand; Mary G Bowring; Alvin G Thomas; Lauren M Kucirka; Allan B Massie; Andrew Cameron; Niraj M Desai; Mark Sulkowski; Dorry L Segev
Journal:  Ann Intern Med       Date:  2018-04-17       Impact factor: 25.391

9.  Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.

Authors:  Nancy Reau; Paul Y Kwo; Susan Rhee; Robert S Brown; Kosh Agarwal; Peter Angus; Edward Gane; Jia-Horng Kao; Parvez S Mantry; David Mutimer; K Rajender Reddy; Tram T Tran; Yiran B Hu; Abhishek Gulati; Preethi Krishnan; Emily O Dumas; Ariel Porcalla; Nancy S Shulman; Wei Liu; Suvajit Samanta; Roger Trinh; Xavier Forns
Journal:  Hepatology       Date:  2018-07-25       Impact factor: 17.425

10.  Inactivating hepatitis C virus in donor lungs using light therapies during normothermic ex vivo lung perfusion.

Authors:  Marcos Galasso; Jordan J Feld; Yui Watanabe; Mauricio Pipkin; Cara Summers; Aadil Ali; Robert Qaqish; Manyin Chen; Rafaela V P Ribeiro; Khaled Ramadan; Layla Pires; Vanderlei S Bagnato; Cristina Kurachi; Vera Cherepanov; Gray Moonen; Anajara Gazzalle; Thomas K Waddell; Mingyao Liu; Shaf Keshavjee; Brian C Wilson; Atul Humar; Marcelo Cypel
Journal:  Nat Commun       Date:  2019-01-29       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.